New members

Welcome to our new Corporate Member: IPSEN

ipsen logo

IPSEN is a mid-sized biopharmaceutical company, working to improve people’s lives and health outcomes by focusing on areas of high unmet medical need.

By rapidly boosting their pipeline to bring the full potential of innovative medicines to the global community, Ipsen has the goal of improving patients’ lives through research, innovation, and the development of transformative medicines for Oncology, Rare Diseases, and Neuroscience.

Founded as a family practice by Dr. Henri Beaufour, who opened Beaufour Laboratories in Dreux (France) in 1929, Ipsen started out creating rosemary-based medicine intended for the treatment of digestive disorders. Nearly 100 years on Ipsen has registered in more than 100 countries and has a presence on every continent.

Led by an experienced group of world-class leaders and experts, today Ipsen is made up of over 5,000 talented and dedicated professionals around the world, all of which work together to develop new and innovative treatments for the people who need them most.

Julien Dagher, General Manager at  Ipsen ANZ, believes that at its core, its people are the driving force behind Ipsen’s ongoing commitment to innovation.

"The passion and commitment of our people is what has allowed Ipsen to develop new and effective therapies, forge valuable partnerships and ultimately continue to improve the lives of patients for over 100 years."

One of Ipsen’s core therapeutic areas is Rare Diseases. By focusing on patient care, through collaboration with community, active listening and feedback cycles, Ipsen strives to understand and address the challenges faced by those living with rare diseases.

These learnings and insights inform their activities both in regard to medical advancement, advocacy and support. As a result, they are making significant scientific breakthroughs in a number of rare disease areas including musculoskeletal (bone), endocrine and neuromuscular disorders while also amplifying patient voices ensuring no-one is left behind.

David Leow, Chief Executive Officer at Ipsen, believes Ipsen’s connection with patients and community is what inspires them to continuously develop new and innovative treatment pathways for patients.

"Being in touch with what matters to patients and their families helps us understand their needs and work together to bring meaningful improvements to their lives."

Beyond its commitment to medical innovation, Ipsen is also focused on minimising its impact on the environment and creating a culture of inclusion and collaboration for all employees.

The organisation is working locally to prioritise the creation of a sustainable future by committing to reducing the energy used in its facilities, minimising the impact of its offices on the environment, transitioning to a greener fleet and implementing science-based targets for approval,

Ipsen also prioritises workplace culture, having made significant investments in creating a culture where collaboration and excellence is championed by all. In 2023 the company was named a Great Place to Work® / Best Place to Work® / Top® Employer across 18 sites worldwide.

This is because organisation believes it is important to empower employees to do their best work. It recognises the challenges of working in a fast-paced environment , and provides its people with the necessary support – both from leaders and colleagues alike – to continue helping improving patients’ lives and outcomes.

Wesbite: Ipsen

Share this page Share on FacebookShare on TwitterShare on Linkedin

Stay informed

Subscribe to our newsletter!


Join our network